Analysts Set Endo International PLC (NASDAQ:ENDP) PT at $5.83

Shares of Endo International PLC (NASDAQ:ENDP) (TSE:ENL) have been given an average rating of “Hold” by the eight brokerages that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $5.83.

A number of research analysts recently issued reports on the company. Citigroup initiated coverage on Endo International in a report on Friday, April 24th. They set a “buy” rating and a $7.00 price target on the stock. ValuEngine downgraded Endo International from a “sell” rating to a “strong sell” rating in a report on Wednesday, June 17th. Morgan Stanley reduced their target price on Endo International from $4.00 to $3.00 and set an “underweight” rating on the stock in a report on Thursday, April 2nd. Piper Sandler reduced their target price on Endo International from $7.00 to $6.00 and set an “overweight” rating on the stock in a report on Wednesday, April 15th. Finally, Royal Bank of Canada restated a “hold” rating and issued a $6.00 price target on shares of Endo International in a research note on Thursday, June 11th.

Shares of NASDAQ ENDP opened at $3.50 on Tuesday. The stock has a market cap of $776.40 million, a PE ratio of -2.87 and a beta of 1.54. Endo International has a fifty-two week low of $1.97 and a fifty-two week high of $7.10. The stock has a fifty day moving average of $3.86 and a 200-day moving average of $4.53.

Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.95 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.55 by $0.40. Endo International had a negative return on equity of 91.00% and a negative net margin of 9.09%. The firm had revenue of $820.40 million during the quarter, compared to analyst estimates of $713.62 million. During the same quarter in the previous year, the company posted $0.60 earnings per share. The company’s revenue was up 13.9% compared to the same quarter last year. Analysts predict that Endo International will post 2.25 EPS for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in ENDP. Geode Capital Management LLC increased its stake in Endo International by 4.0% in the 1st quarter. Geode Capital Management LLC now owns 3,315,646 shares of the company’s stock worth $12,267,000 after buying an additional 126,177 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Endo International by 0.3% during the fourth quarter. Bank of New York Mellon Corp now owns 2,376,454 shares of the company’s stock valued at $11,145,000 after purchasing an additional 6,648 shares in the last quarter. Rhumbline Advisers grew its position in shares of Endo International by 6.6% during the first quarter. Rhumbline Advisers now owns 636,168 shares of the company’s stock valued at $2,354,000 after purchasing an additional 39,240 shares in the last quarter. Russell Investments Group Ltd. grew its position in shares of Endo International by 37.3% during the first quarter. Russell Investments Group Ltd. now owns 227,911 shares of the company’s stock valued at $842,000 after purchasing an additional 61,911 shares in the last quarter. Finally, Comerica Bank grew its position in shares of Endo International by 4.0% during the first quarter. Comerica Bank now owns 197,472 shares of the company’s stock valued at $814,000 after purchasing an additional 7,510 shares in the last quarter. 82.32% of the stock is currently owned by institutional investors and hedge funds.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Featured Story: Most Active Stocks

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.